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Summary
Objective: Mesenchymal stromal cells (MSC) are a promising tool for tissue engineering of the intervertebral disc (ID). The IDs are charac-
terized by hypoxia and, after degeneration, by an inﬂammatory environment as well. We therefore investigated the effects of inﬂammation
induced with interleukin (IL)-1b and of hypoxia (2% O2) on the chondrogenic differentiation of MSC.
Methods: Bone-marrow-derived MSC (bmMSC) were cultured in a fetal-calf-serum-free medium and characterized according to the minimal
criteria for multipotent MSC. Chondrogenic differentiation of MSC was induced following standard protocols, under hypoxic conditions, with or
without IL-1b supplementation. After 28 days of differentiation, micromasses were analyzed by histochemical staining and immunohistochem-
istry and by determining the mRNA level of chondrogenic marker genes utilizing quantitative RT-PCR.
Results: Micromasses differentiated under IL-1b supplementation are smaller and express less extracellular matrix (ECM) protein. Micro-
masses differentiated under hypoxia appear larger in size, display a denser ECM and express marker genes comparable to controls. The
combination of hypoxia and IL-1b supplementation improved chondrogenesis compared to IL-1b supplementation alone. Micromasses differ-
entiated under standard conditions served as controls.
Conclusion: Inﬂammatory processes inhibit the chondrogenic differentiation of MSC. This may lessen the regenerative potential of MSC in
situ. Thus, for the cell therapy of IDs using MSC to be effective it will be necessary to manage the inﬂammatory conditions in situ. In contrast,
hypoxic conditions exert beneﬁcial effects on chondrogenesis and phenotype stability of transplanted MSC, and may improve the quality of the
generated ECM.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Degeneration of the intervertebral disc (ID) is one of the
most widespread health problems in the industrialized
world, causing substantial economic damage1,2. Histologi-
cally, a healthy ID is characterized by low cell density with
a high proportion of extracellular matrix (ECM) and is with-
out blood and lymphatic vessels or innervation3. Avascular
discs have no access to regenerative cells in case of dam-
age, and the low intrinsic regenerative capacity furtheraTel: 49-7071-2981240.
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1368exacerbates degeneration of the ID. This process is accom-
panied by a progressive loss of cells and proteoglycans4,5
in the nucleus pulposus (NP), an increased risk for disrup-
tions of the annulus ﬁbrosus (AF) and changes in the bio-
mechanical properties of the ID.
Current therapeutic options to prevent further degenera-
tion of traumatized IDs include reduction of inﬂammation
and pain by drugs, physical therapy, removal of extruded
tissue or implantation of artiﬁcial discs. Most of these thera-
pies focus on the treatment of symptoms6. Cell-based ther-
apies for the biological reconstruction of the injured tissue
are largely in a developmental stage. Cells suitable for
use in a cell therapy include autologous cells of the ID1
and adult mesenchymal stromal cells (MSC)7. In animal
models, a retardation of disc degeneration was reported af-
ter implantation of cells from the NP into the ID8,9. However,
a major disadvantage of regimens based on transplantation
of autologous cells into a degenerated or injured ID is the
fact that only low numbers of suitable cells can be isolated,
and the harvested cells often turn out to proliferate at low
rates. Compensating for the low numbers of NP-cells
through expansion in vitro over long periods of time would
1369Osteoarthritis and Cartilage Vol. 17, No. 10increase the risk of dedifferentiation of the chondrocytes
into a ﬁbroblast-like phenotype10. Such cells regenerate
a ﬁbrous, scar-like tissue rather than the proteoglycan-rich
tissue needed for regeneration of the NP. In addition, the
regenerative power of autologous cells isolated from a de-
generated disc would probably not be sufﬁcient. Because
of these problems, adult MSC are attracting increasing in-
terest as an alternative strategy for cellular regeneration11.
MSC are characterized by a high proliferation capacity
and the ability to differentiate into several lineages. MSC dif-
ferentiated along the chondrogenic lineage display a pheno-
type similar to that of cells in the ID12. In particular, the gene
expression of important ECM components of the ID, such
as type II collagen or aggrecan, is signiﬁcantly increased
in chondrogenically differentiated MSC12. Furthermore, co-
cultures of human MSC and NP-cells with cellecell contact
facilitated the differentiation of MSC into an NP-cell like phe-
notype13. Again, one limiting factor for the translation of
such a strategy into clinical success could be the quality
and numbers of autologous NP-cells available from affected
discs. We therefore focused this study on improving the
chondrogenic differentiation of MSC only.
During expansion in vitro up to the point of injection into the
NP,MSCare exposed to unphysiological conditions. Once in
situ, they are likely to face a hypoxic environment (as low as
1%O2)
14e17 and in somecases, an inﬂammatory one aswell.
In the degenerated ID the expression of matrix-degrading
proteases such as matrix metalloproteinase (MMP)-1, -3,
and -13was noted in theNPand in the inner AF18. This would
certainly have an impact on the chondrogenic capacity of any
transplanted cells. To achieve adequate survival rates of the
transplanted MSC and sufﬁcient chondrogenic capacity, it is
necessary to analyze the inﬂuences towhich theMSCare ex-
posed in situ in order to develop strategies to prepare the cells
for those conditions. Inﬂammatory mediators such as inter-
leukin (IL)-1b or tumor necrosis factor (TNF)-a have unfavor-
able effects ondifferentiated chondrocytesorMSC.Thegene
expression of key components of the ECM in ID, i.e., type II
collagen and aggrecan, was particularly affected19,20. In con-
trast, hypoxia has been shown to have beneﬁcial effects on
phenotype stability of bovine articular chondrocytes21. Hyp-
oxia facilitated chondrogenesis of rat MSC22 and human ad-
ipose-derived stem cells23,24. In this study we investigated
the inﬂuences of inﬂammatory and hypoxic conditions sepa-
rately and in combination on the chondrogenic differentiation
of human bone-marrow-derived MSC (bmMSC).
In order to reach the ultimate goal of establishing cell
therapies for patients, it is important to develop Good
Manufacturing Practice (GMP)-compatible protocols for
the isolation, expansion and differentiation of the cells.
The use of fetal calf serum (FCS) in cell cultures represents
a fundamental problem. Its use in tissue engineering is as-
sociated with many risks, including viral and prion transmis-
sion or disadvantageous immune responses, making FCS
unsuitable for therapeutic applications25e27. In order to
meet GMP requirements, it has been suggested that human
serum should be used in place of FCS28e30. In this study we
used a GMP-compatible expansion medium containing
human plasma and platelet concentrate29.Materials and methodsISOLATION OF HUMAN MSC AND CELL CULTUREBone-marrow aspirates were obtained from the BGU Center for Trauma-
tology, Tu¨bingen from the femur shaft of 28 patients undergoing total hip
replacement after approval by the ethics committee of the University of
Tu¨bingen. The age of the donors ranged from 45 to 83 years. HumanMSC were isolated using Ficoll density gradient fractionation (Ficoll-paque
plus, Amersham Biosciences, 400 g, 30 min, room temperature, RT).
Mononucleated cells in the interphase were collected, washed with phos-
phate buffered saline (PBS) (Lonza, Basel, Switzerland) and seeded in
75 cm2 cell culture ﬂasks (BD Bioscience, Heidelberg, Germany), at a den-
sity of 2 105 cells/cm2. After 24 h of incubation at 37C, 5% CO2 in humid-
iﬁed atmosphere, non-adherent cells were removed. MSC were expanded
in medium as described by Mueller et al.29. This fresh frozen plasma plate-
let (FFPP) medium is composed of low-glucose DMEM (Dulbecco’s Modi-
ﬁed Eagle Medium, Lonza) supplemented with 5% human fresh frozen
plasma (FFP), 108/ml platelets (University of Tu¨bingen, Blood Donor Cen-
ter), 2 mM glutamine (Lonza), 1000 IU heparin sodium (Roth, Karlsruhe,
Germany), 100 U/ml penicillin, and 100 mg/ml streptomycin (Invitrogen,
Karlsruhe, Germany). The expansion medium was changed twice
a week. When MSC reached 80% of conﬂuence, the cells were detached
with accutase (PAA, Pachingen, Austria) and seeded at an inoculation den-
sity of 3 103 cells/cm2. A commercially available MSC medium served as
control medium in some experiments (MSCGM, Lonza).CHARACTERIZATION OF HUMAN MSCMSC were characterized according to deﬁned minimal criteria for multipo-
tent MSC31. To determine the proliferation capacity of MSC in FFPP, MSC
were expanded in FFPP and compared to MSC expanded in commercially
available medium (MSCGM, Lonza) over four consecutive passages
(4 weeks’ total), followed by induction of differentiation into the adipogenic,
osteogenic and chondrogenic lineages.
For adipogenic differentiation 5 104 cells/well were seeded in 6-well
plates (Greiner Bio One, Essen, Germany) and cultured in adipogenic induc-
tion medium containing DMEM high glucose (Invitrogen, Karlsruhe, Ger-
many), 10% FCS (Biochrom, Berlin, Germany), 100 IU/ml penicillin,
100 mg/ml streptomycin (Invitrogen), 0.2 mM indomethacin (Calbiochem,
San Diego, USA), 0.01 mg/ml insulin, 1 mM dexamethasone and 0.5 mM
3-isobutylxanthine (both SIGMA-Aldrich, Steinheim, Germany). After 28
days of incubation in adipogenic induction medium, the monolayer cultures
were stained with Oil Red O solution (SIGMA-Aldrich) and examined by light
microscopy.
For osteogenic differentiation 5 104 cells/well were seeded in 6-well
plates and cultured in osteogenic induction medium containing DMEM high
glucose 10% FCS, 100 IU/ml penicillin, 100 mg/ml streptomycin, 10 mM b-
glycerophosphate (Merck, Darmstadt, Germany), 1 mM dexamethasone
and 0.17 mM ascorbic acid 2-phosphate (SIGMA-Aldrich). After 28 days in
osteogenic induction medium, the monolayer cultures were stained with aliz-
arin red S (SIGMA-Aldrich) and using the von Kossa staining protocol32.
Micromass cultures were used for chondrogenic differentiation. In this pro-
cedure, 4 105 cells were seeded in 20 ml chondrogenic induction medium
containing DMEM high glucose, 0.17 mM ascorbic acid 2-phosphate,
100 IU/ml penicillin, 100 mg/ml streptomycin, 0.1 mM dexamethasone, an in-
sulin, transferrin, sodium selenite, and linoleic acid, 1 ITSþ 1 supplement
(SIGMA-Aldrich), 0.35 mM L-proline (SIGMA-Aldrich) and 10 ng/ml trans-
forming growth factor (TGF)-b3 (R&D Systems, Minneapolis, USA) in a round
well of a 96-well plate (Greiner Bio One). After 2 h, 200 ml chondrogenic
induction medium was added to the adherent cells. For chondrogenic
differentiation under inﬂammatory conditions, the chondrogenic induction
medium was supplemented with 2 ng/ml recombinant interleukin-1 beta
(rhIL-1b, R&D Systems). Chondrogenic differentiation under hypoxia was
performed using a reduced oxygen concentration (2% O2, 37
C, humidiﬁed
atmosphere, Hypoxia Workstation, Ruskinn, Bridgend, UK). After 28 days,
micromass pellets were harvested and characterized by Alcian blue
(SIGMA-Aldrich) and immunostaining of type I and type II collagens (mono-
clonal antibodies (mAB) for collagen type I and collagen type II, MP Biomed-
icals, Eschwege, Germany) on cryoslides. In addition, mRNA expression of
relevant marker genes, especially collagen-1a2, collagen-2a1, collagen-10,
aggrecan, BMP-2 (bone morphogenetic protein-2), IL-1b, CD-RAP (carti-
lage-derived retinoic acid-sensitive protein) as a regulator of chondrogene-
sis33, SRY (sex determining region Y)-box 6 (SOX-6) and SOX-9, and
MMP-1, -3 and -13 were analyzed by quantitative reverse transcription fol-
lowed by polymerase chain reaction (qRT-PCR).EXPRESSION OF CELL SURFACE ANTIGENSThe expression of CD90, CD14, CD11b (R&D Systems), CD105, CD73,
CD45 and CD34 (BD Pharmingen, San Diego, USA) on MSC was analyzed
by ﬂow cytometry. Cells were detached gently using Accutase. Unspeciﬁc
binding of antibodies via Fc-receptors was blocked with Gamunex (Talecris
Biotherapeutics, Frankfurt, Germany). Then the MSC were washed twice
with PFEA buffer (PBS, 2% FCS, 2 mM EDTA, 0.01% sodium azide) and in-
cubated for 20 min at 4C with phycoerythrin (PE)-conjugated or allophyco-
cyanin (APC)-conjugated mAB. Unbound antibodies were washed away
twice with PFEA buffer and the cells were analyzed by ﬂow cytometry (BD
LSRII, San Diego, USA). Unstained cells served as controls. Data were eval-
uated using the software FlowJo (Tree Star, Inc., Ashland, Oregon, USA).
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lution (SIGMA-Aldrich) using a plastic pestle. RNAwas isolatedwith theRNeasy
Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. Re-
verse transcription into cDNA was performed on 1 mg total RNA using the
Advantage RT for PCR Kit (Clontech, Mountain View, USA). Gene-speciﬁc
cDNA was enumerated by quantitative RT-PCR (qRT-PCR, LightCycler,
Roche, Mannheim, Germany) utilizing commercially available primer pairs for
collagen-1a2, collagen-2a1, collagen-10, aggrecan, BMP-2, IL-1b, CD-RAP,
SOX-6, SOX-9, MMP-1, MMP-3 and MMP-13 (SearchLC, Heidelberg, Ger-
many). Serial dilutions of recombinant DNA standards served as controls. b-
actin served as the reference gene in each PCR is explained in qRT-PCR
above.STATISTICAL ANALYSISThe mean values and standard deviations (SDs) were computed from the
individual experiments utilizing MS Excel. A test for analysis of variance
(ANOVA, KruskaleWallis, GraphPad InStat3) and post-hoc test were per-
formed for statistical evaluation. P values below 0.05 were considered to
be statistically signiﬁcant. Data on mRNA expression represent the ratio to
the reference gene b-actin and are expressed as means SD from individ-
ual experiments.ResultsCHARACTERIZATION OF MSC UPON EXPANSION
IN FFPP MEDIUMTo characterize MSC expanded in FFPPmedium, we com-
pared their morphology, proliferation rate, differentiation ca-
pacity and expression of surface antigens. MSC expanded
either in FFPP medium or in MSCGM containing FCS were
able to adhere to plastic but displayed morphological differ-
ences. MSC expanded in MSCGM appeared more spread
out than MSC expanded in FFPP medium (not shown).
Furthermore, thenumberofMSCsgenerated inFFPPmedium
(passage 4: mean 1.9 107 1.91 106) was signiﬁcantly
higher than the number of MSCs after expansion in MSCGM
(passage 4: median 4.8 106 1.64 106; P< 0.001,
Fig. 1). TheMSC are classiﬁed by the expression of a number
of cell surface antigens. On MSC expanded in FFPPmedium
the expression of CD73, CD90 and CD105 was detected by
ﬂow cytometry. At the same time the expression of CD11b,
CD45 and CD34 in these cells was low or completely absent.
A similar expression proﬁle of surface antigens was found on
MSC expanded in MSCGM (Fig. 2).Fig. 1. Proliferation of MSC. Displayed are mean values and SD of
numbers of MSC from three donors expanded over four passages
either in FCS-free FFPP medium (red line) or in FCS-containing
MSCGM medium (black line). MSC expanded in FCS-free FFPP
medium are characterized by signiﬁcantly higher proliferation rates
than MSC expanded in FCS-containing MSCGM medium.DIFFERENTIATION OF MSC IN VITROAfter 4 weeks of expansion, differentiation of MSC was
induced and analyzed by cytochemical staining, histochem-
ical staining and immunostaining. MSC expanded for 4
weeks in either MSCGM or FFPP medium maintained their
ability to differentiate into the adipogenic, osteogenic and
chondrogenic lineages. After 28 days in adipogenic induc-
tion medium MSC were ﬁlled with lipid vesicles and were
positive for oil-red staining [Fig. 3(a) and (b)]. The accumu-
lation of calcium in cells after 28 days of osteogenic induc-
tion was detected by von Kossa staining [Fig. 3(c) and (d)]
and alizarin red (not shown). The deposition of proteogly-
cans during the chondrogenic differentiation was detected
by Alcian blue staining [Fig. 3(e) and (f)]. Expansion of
MSC in FFPP did not change their differentiation capacity
in vitro compared to MSC expanded in MSCGM. We there-
fore continued our experiments with MSC expanded in the
GMP-compatible FFPP medium only.CHONDROGENIC DIFFERENTIATION UNDER INFLAMMATORY
AND HYPOXIC CONDITIONSChondrogenic differentiation of MSC in the presence of IL-
1bproducedmicromasspellets thatwere smaller [Fig. 4(b);B
mean 0.95 mm 0.13 mm] than those generated by stan-
dard differentiation [Fig. 4(a); B mean 1.69 mm 0.26 mm].
Minute tissue fragments (B 100 mm) were observed in the
presence of IL-1b and the tissue was frequently disrupted
whenmicrosections were prepared [Fig. 4(b)]. This indicated
that the generated ECM was not of sufﬁcient mechanical
strength. Chondrogenic differentiation in the presence of IL-
1b under hypoxia resulted in slightly increased dimensions
of the pellets [Fig. 4(c); B mean 1.05 mm 0.18 mm]
when compared to differentiation in presence of IL-1b under
normoxia [Fig. 4(b)]. In contrast, larger dimensions of carti-
lage micromasses were observed after differentiation
of MSC under hypoxic conditions [Fig. 4(d); B mean
2.13 mm 0.28 mm] when compared to differentiation ac-
cording to the standard protocol [Fig. 4(a)].
The accumulation of proteoglycan and of type I and type
II collagens in micromasses generated under different con-
ditions was investigated by histological and immunological
staining. The addition of IL-1b to differentiation media under
normoxia generated micromasses with a weak Alcian blue
staining, a sign of weak accumulation of ECM, especially
of proteoglycans [Fig. 4(f)]. Differentiation in the presence
of IL-1b under hypoxia resulted in more intense Alcian
blue staining [Fig. 4(g)] than differentiation with IL-1b under
normoxia [Fig. 4(f)], but less intense staining than that of the
controls [Fig. 4(e)]. In samples differentiated under hypoxia
we detected a more intense Alcian blue staining [Fig. 4(h)]
compared to controls [Fig. 4(e)]. Similar staining patterns
were achieved by immunohistochemistry with mAB to type
I and type II collagens; after differentiation of MSC in the
presence of IL-1b we did not detect any staining of type I
and type II collagens [Fig. 4(j) and (n)]. Differentiation in
the presence of IL-1b under hypoxia generated pellets
that contained some type I collagen at the rim and a rather
weak type II collagen staining all over the micromass
[Fig. 4(k) and (o)]. Hypoxic differentiation of MSC yielded
cells that produced type I and type II collagens throughout
the micromass [Fig. 4(l) and (p)], and signal intensity was
stronger than in the controls [Fig. 4(i) and (m)].
For a speciﬁc analysis of the inﬂuences of inﬂammatory
and/or hypoxic conditions, we investigated the mRNA ex-
pression of chondrogenic marker genes (Table I). Under
Fig. 2. Immunophenotype. Flow cytometric analysis of cell surface antigens of MSC expanded in FCS-free FFPP medium revealed expres-
sion of CD73, CD90, CD105 and a lack of expression of CD11b, CD34 and CD45. The histograms display the ﬂuorescence proﬁles of MSC
stained with the mAB (red lines) and the unstained controls (green lines).
1371Osteoarthritis and Cartilage Vol. 17, No. 10standard conditions, the expression of type I collagen was
signiﬁcantly augmented (P< 0.01) after chondrogenic
differentiation compared to MSC. Furthermore, expression
of type II and type X collagens, aggrecan, and CD-RAP
was raised 103- to 106-fold (P< 0.001; Table I). A robust,
10- to 100-fold increase was also observed for the expres-
sion of SOX-6 (P< 0.01), SOX-9 (P< 0.001) and BMP-2
(P< 0.05). Comparing transcript levels in cells after chon-
drogenic differentiation under standard conditions and in
cells after differentiation under inﬂammatory conditions
revealed a signiﬁcant reduction of mRNAs encoding type I
(P< 0.01), type II and type X collagens (P< 0.05), aggre-
can (P< 0.01), SOX-6 (P< 0.01) and SOX-9 and CD-
RAP (P< 0.001). Transcripts encoding BMP-2 remained
high, whereas IL-1b was increased 10-fold (Table I). Chon-
drogenic differentiation under a combination of inﬂamma-
tory and hypoxic conditions yielded a 10- to 100-fold
increase of transcript levels of type II collagen (P< 0.05),
aggrecan and CD-RAP (P< 0.001) compared to chondro-
genic differentiation under inﬂammatory conditions alone.
Transcript levels of type I and X collagens, BMP-2, IL-1b
and SOX-6 did not reveal any signiﬁcant variation. Under
hypoxia, mRNA expression of most factors was not signiﬁ-
cantly changed compared to standard conditions.Expression of IL-1b was detectable at low levels in MSC
(ﬁve of eight donors) and in differentiated cells using the
standard protocol (three of eight donors). A 10-fold increase
in the IL-1b mRNA level was observed under inﬂammatory
conditions alone and in combination with hypoxia (eight of
eight donors). With chondrogenic differentiation under hyp-
oxia alone, IL-1b mRNA expression was detectable in only
two of eight donors (Table I). The mRNA expression of the
proteinases MMP-1 and -3 was signiﬁcantly increased
by IL-1b (MMP-1: P< 0.01; MMP-3: P< 0.05), but this in-
crease was ameliorated by hypoxia (Table I). Furthermore
MMP-1 expression levels were lower under hypoxia than
under normoxia. MMP-13 showed a signiﬁcantly increased
mRNA expression after chondrogenic differentiation
(P< 0.05) but minor differences between the several differ-
entiation conditions. The lowest expression of MMP-13 was
found under hypoxia (Table I).Discussion
For tissue engineering of the ID, adult MSC could be an
alternative to autologous cells from the ID tissue itself1,7.
The generation of sufﬁcient numbers of cells for
Fig. 3. Differentiation capacity of MSC. MSC were expanded in FFPP or MSCGM medium without induction of differentiation. On day 28 of
expansion differentiation was induced. A similar differentiation into adipogenic (a, b), osteogenic (c, d) and chondrogenic (e, f) lineages was
observed from MSC expanded in FCS-free FFPP medium (a, c, e) and FCS-containing MSCGM medium (b, d, f): Oil Red O staining (a, b)
shows adipocytes ﬁlled with lipid vesicles. Von Kossa staining (c, d) indicates calciﬁed areas generated by osteoblasts. Alcian blue staining (e,
f) illustrates proteoglycan distribution of prepared 7 mm cryosections in micromasses. Scale bars¼ 200 mm.
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use of autologous cells for therapy. This problem could be
solved by utilizing MSCs, which are characterized by high
proliferation capacity. To investigate this possibility, we ﬁrst
examined a novel, FCS-free and GMP-compatible medium
supplemented with pooled human plasma and platelet con-
centrate for the expansion of MSC29. Platelet-derived
growth factors have been shown to have a positive effect
on the proliferation of stromal cells34. We conﬁrm that pro-
liferation of MSC in FFPP medium is higher than in
MSCGM. Accelerated growth of differentiation-competent
MSC reduces the time span required to generate the quan-
tities of MSC needed for clinical applications. In addition to
faster availability, MSC can be utilized at lower passages,
which has a beneﬁcial effect on their differentiation and re-
generative capabilities35. Applying the minimal criteria fordeﬁning MSC31, we conclude that the GMP-compatible
MSC expansion medium used in this study is a suitable re-
placement for media containing FCS.
Degeneration of IDs is frequently accompanied by inﬂam-
matory processes. Among other cytokines, the inﬂamma-
tory cytokine IL-1b is involved in the destruction of
cartilage matrix in chondrodestructive diseases36 and is
therefore in the focus of this study. IL-1b displays a clear ef-
fect on the chondrogenic differentiation of MSC. IL-1b in-
duced its own expression, a signiﬁcantly weaker mRNA
expression of ECM components of IDs, and higher expres-
sion of ECM-degrading proteases. Decreased mRNA ex-
pression of SOX-9, Col2A1 and aggrecan was reported
after IL-1b treatment of chondrogenic differentiated human
multipotential mesenchymal cells19, corroborating our
results.
Fig. 4. Characterization of chondrogenically differentiated micromass pellets under inﬂuence of IL-1b, under hypoxia in presence of
IL-1b, and under hypoxia. Morphology of generated micromass pellets. Pictures of micromasses were taken in cell culture wells after 4
weeks of chondrogenic differentiation (aed; scale bars¼ 200 mm). The expression of proteoglycan in micromasses was detected in frozen
sections by Alcian blue staining (eeh; scale bars¼ 200 mm). Note that IL-1b reduced Alcian blue staining intensity to a pale blue, indicating
low aggrecan expression (f). The expression of type I (iel) and type II (mep) collagens was investigated in frozen sections by immunohisto-
chemistry. Nuclei were counterstained with 4‘,6-Diamidino-2-phenylindole (DAPI). The ﬁgure presents the overlay of micrographs utilizing the
PE and DAPI channels (iep) (size bars¼ 200 mm).
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the elevated expression of ECM-degrading proteases are
mirrored by histochemical staining and immunostaining of
micromasses: in the presence of IL-1b a weak accumulation
of proteoglycans, type I and type II collagens was noted. As
a consequence, micromass pellets remained smaller than
controls and also displayed disruption of the ECM structure.
In several cases the inner part of the pellet failed to com-
pletely regenerate an ECM (not shown). We conclude that
the inﬂammatory processes have a negative effect on either
the chondrogenic differentiation potential of MSC or on the
matrix production of cells in this environment. For any cell
therapy of the IDs using MSC to be effective, it will therefore
be necessary to develop strategies to ensure the steady ex-
pression of ECM proteins by limiting inﬂammatory stimuli.
Potential strategies for reducing IL-1b activity using, forexample, IL-1 receptor antagonist, IL-1b mAB, the IL-1
Trap and inhibitors of IL-1b-converting enzyme are in
progress37,38.
In contrast to inﬂammatory processes, hypoxia, the sec-
ond factor investigated in this study, elicits positive effects
on the chondrogenic differentiation potential of MSC. Re-
cent studies using different species have shown a hyp-
oxia-induced enhancement of chondrogenesis by
induction of gene expression of ECM components and
chondrogenic transcription factors, as well as augmented
deposition of type I and type II collagens and proteogly-
can22e24,39,40. There is evidence that hypoxia-inducible fac-
tor (HIF)-1alpha plays a key role in the effects of hypoxia on
chondrogenesis22,24 and expression of HIF-1alpha could be
stimulated by growth factors in vitro41. In addition to the ef-
fects of low oxygen on chondrogenic differentiation of MSC
Table I
mRNA expression of marker genes after chondrogenic differentiation under influence of IL-1b
Collagen-1a2 Collagen-2a1 Collagen-10 Aggrecan SOX-6 SOX-9
MSC 1.92Eþ00 8.64E07 6.99E04 3.34E04 7.10E05 1.24E03
SD 8.22E01 1.20E06 5.66E04 4.78E04 3.88E05 1.01E03
N 1.22Eþ01 2.59Eþ01 1.15Eþ00 8.88E01 2.36E03 7.97E02
SD 9.92Eþ00 4.36Eþ01 9.78E01 1.10Eþ00 1.79E03 3.68E02
I 2.26Eþ00 3.19E04 2.04E02 7.64E04 7.71E05 5.45E03
SD 2.32Eþ00 3.59E04 2.88E02 6.84E04 5.60E05 2.27E03
HI 4.26Eþ00 2.27E02 2.45E02 8.42E03 1.38E04 1.04E02
SD 3.24Eþ00 3.63E02 1.34E02 4.78E03 6.22E05 2.19E03
H 7.37Eþ00 8.68Eþ00 1.01Eþ00 3.95E01 1.89E03 9.78E02
SD 3.08Eþ00 7.24Eþ00 1.33Eþ00 3.03E01 1.89E03 1.28E01
Comparison P values
MSC vs N P[ 0.0025 P[ 0.0002 P[ 0.0002 P[ 0.0003 P[ 0.0037 P[ 0.0002
MSC vs I P> 0.9999 P¼ 0.0578 P¼ 0.0504 P¼ 0.1206 P¼ 0.8169 P¼ 0.0548
MSC vs HI P¼ 0.2788 P¼ 0.0512 P¼ 0.0512 P¼ 0.0516 P¼ 0.1833 P¼ 0.0509
MSC vs H P[ 0.0386 P[ 0.0002 P[ 0.0003 P[ 0.0003 P[ 0.0112 P[ 0.0002
N vs I P[ 0.0011 P[ 0.0239 P[ 0.0263 P[ 0.0027 P[ 0.0026 P[ 0.0201
N vs HI P¼ 0.0848 P¼ 0.0521 P¼ 0.0598 P¼ 0.0512 P¼ 0.0524 P¼ 0.0523
N vs H P¼ 0.2345 P¼ 0.3823 P¼ 0.0535 P¼ 0.3823 P¼ 0.3357 P¼ 0.4418
I vs HI P¼ 0.3758 P[ 0.0126 P¼ 0.3758 P[ 0.0009 P¼ 0.1939 P[ 0.0093
I vs H P[ 0.0195 P[ 0.0002 P¼ 0.0503 P[ 0.0241 P[ 0.0391 P[ 0.0121
HI vs H P¼ 0.1939 P¼ 0.0512 P[ 0.0167 P¼ 0.0601 P¼ 0.0516 P¼ 0.0610
BMP-2 CD-RAP IL-1b MMP-1 MMP-3 MMP-13
MSC 2.97E04 2.21E05 7.89E06 2.61E04 5.01E04 1.39E04
SD 2.64E04 2.79E05 1.01E05 2.86E04 9.84E04 7.28E05
N 1.88E02 5.49E02 1.97E05 1.17E03 1.33E02 4.56E02
SD 7.60E03 5.32E02 3.23E05 2.62E03 7.95E03 2.30E02
I 4.57E02 5.50E04 1.80E04 4.30E02 2.74E01 1.38E01
SD 3.23E02 5.14E04 3.93E04 3.76E02 2.54E01 1.08E01
HI 3.12E02 6.51E03 2.91E04 1.05E02 1.24E01 1.05E01
SD 1.21E02 2.63E03 4.51E04 6.83E03 1.78E01 5.35E02
H 2.37E02 6.48E02 5.87E06 2.84E04 1.70E02 1.87E02
SD 1.38E02 4.91E02 1.65E05 2.95E04 1.85E02 1.57E02
Comparison P values
MSC vs N P[ 0.0368 P[ 0.0003 P¼ 0.9153 P¼ 0.6991 P¼ 0.0556 P[ 0.0129
MSC vs I P[ 0.0003 P[ 0.0513 P¼ 0.0507 P[ 0.0225 P[ 0.0128 P[ 0.0043
MSC vs HI P¼ 0.0667 P¼ 0.0567 P¼ 0.1333 P¼ 0.0538 P¼ 0.0538 P[ 0.0097
MSC vs H P[ 0.0484 P[ 0.0003 P¼ 0.2189 P¼ 0.6623 P¼ 0.0643 P¼ 0.0503
N vs I P¼ 0.0830 P¼ 0.0535 P¼ 0.0501 P[ 0.0043 P[ 0.0226 P¼ 0.4286
N vs HI P¼ 0.1939 P¼ 0.0532 P¼ 0.1343 P¼ 0.0714 P¼ 0.0514 P¼ 0.0952
N vs H P¼ 0.8865 P¼ 0.5054 P¼ 0.5516 P¼ 0.4286 P¼ 0.9307 P¼ 0.0519
I vs HI P¼ 0.4970 P[ 0.0009 P¼ 0.7758 P¼ 0.1958 P¼ 0.2619 P> 0.9999
I vs H P¼ 0.1893 P[ 0.0212 P[ 0.0193 P[ 0.0403 P[ 0.0173 P¼ 0.0952
HI vs H P¼ 0.6667 P¼ 0.0586 P¼ 0.0542 P¼ 0.0557 P¼ 0.3929 P¼ 0.0557
Transcript levels of marker genes including SD normalized to b-actin of bmMSC before (MSC) and after chondrogenic differentiation under
standard conditions (N), in presence of IL-b (I), in presence of IL-b and under hypoxia (HI), or under hypoxia (H). The mean values of the
normalized transcript levels (bold italics)SD (italics) were computed from the individual experiments, and an ANOVA test (KruskaleWallis)
and post-hoc test were performed for statistical evaluation. P values below 0.05 were considered to be statistically signiﬁcant (bold).
1374 T. Felka et al.: MSC at inﬂammation and hypoxiaderived from different origins22,24 hypoxia also supports the
chondrogenic potential of mature articular chondrocytes
during expansion21.
A comparison of the chondrogenic differentiation at hyp-
oxia vs normoxia reveals enhanced deposition of ECM
components in micromasses under hypoxia. This did not
correlate with an increased mRNA expression of ECM com-
ponents or other chondrogenic factors. Instead, the chon-
drogenic beneﬁts of hypoxia correlated with a slightly
reduced expression of IL-1b, which in turn would block its
autocrine regulation and effects on the expression of
MMP-1 and MMP-3. In the presence of IL-1b, hypoxia did
not signiﬁcantly regulate the expression of IL-1b, but it did
allay the IL-1b-associated reduction of type II collagen, ag-
grecan, SOX-9 and CD-RAP expression and in addition itlowered the expression of the cartilage-degrading prote-
ases MMP-1 and MMP-3. The chondrogenic beneﬁt of hyp-
oxia in our experiments did not seem to be associated with
an up-regulation of the expression of chondrogenic factors,
but rather with the reduction of the pro-inﬂammatory effects
caused by IL-1b.
MSC differentiated under normoxic or hypoxic conditions
expressed increased amounts of type I and II collagens, but
also displayed increased expression of type X collagen
mRNA. Type X collagen is a marker of chondrocyte hyper-
trophy, and its expression is associated with endochondral
ossiﬁcation42,43. Our results indicate that the chondrogenic
differentiation of MSC under hypoxia does not prevent the
expression of type X collagen. Induction of type X collagen
is dependent on methylation patterns of its promoter44 and
1375Osteoarthritis and Cartilage Vol. 17, No. 10its expression can be suppressed in vitro by modiﬁcation of
the tissue culture vessels45, but not by hypoxia.
Prior to any clinical application of MSC in ID regeneration,
other issues must be addressed in addition to IL-1b and hyp-
oxia. Among these are the cellular microenvironment and
paracrine signals inﬂuencing chondrogenic differentiation in
situ. Furthermore, expansion of MSC in co-culture with NP-
cells or culture of MSC in suitable scaffolds improved chon-
drogenic differentiation of MSC13,46e48. However, in this
study we focused on effects of hypoxia and inﬂammation
on MSC differentiation. In summary, we conclude that hyp-
oxia stabilizes the chondrogenic differentiation processes
even in an inﬂammatory environment.Conﬂict of interest
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